---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-017376"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-24T00:03:16.298415+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Q2 revenue $145M (+231% YoY); guides total revenue to $425-440M

## Summary
- Foundry revenue $44M (+105% YoY); added 13 new Cell Programs in Q2.
- Biosecurity revenue $100M with 36% gross margin; expects at least $260M for FY 2022.
- Adjusted EBITDA improved to -$23M from -$38M YoY; cash balance ~$1.4B.
- Pending acquisitions of Zymergen (all-stock) and Bayer's West Sacramento facility expected to close Q4 2022 / Q1 2023.
- Dr. Kathy Hopinkah Hannan appointed to board of directors.

## SEC filing metadata
- accession: 0000950170-22-017376
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000095017022017376/0000950170-22-017376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000095017022017376/dna-20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-017376
- JSON: https://secwatch.observer/filing/0000950170-22-017376.json
- Plain text: https://secwatch.observer/filing/0000950170-22-017376.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.